Induction of Antinuclear Antibody after Interferon Therapy in Patients with Type-C Chronic Hepatitis: Its Relation to the Efficacy of Therapy

References

• Mishiro S, Hoshi Y, Takeda K, Yoshikawa A, Gotanda T, Takahashi K, et al. Non A nonB hepatitis specific antibodies directed at host‐derived epitope: implication for an autoimmune process. Lancet 1990; 336: 1400–3
   PubMed Web of Science ®Google Scholar
• Lenzi M, Ballaraini G, Fusconi M, Cassani F, Selleri L, Volta U, et al. Type 2 autoimmune hepatitis and hepatitis C infection. Lancet 1990; 335: 258–9
   PubMed Web of Science ®Google Scholar
• Pawlotsky J M, Deforges L, Bretagne S, André C, Métreau J M, Thiers V, et al. Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis. Gut 1993; S66–8, Suppl
   Google Scholar
• Kiyosawa K, Seki T, Tanaka E, Sodeyama T, Furuta K, Furuta S, et al. Comparison of the immunogenetic features between patients with autoimmune hepatitis and patients with type C chronic active hepatitis. Gastroenterol Jpn 1993; 28: 63–8
   PubMedGoogle Scholar
• Meyet W J, Hess G, Gerken G, Rossol S, Voth R, Manns M, et al. Treatment of chronic type B hepatitis with recombinant alfa interferon induces autoantibody not specific for autoimmune chronic hepatitis. Hepatology 1989; 10: 24–8
   PubMedGoogle Scholar
• Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L, et al. Autoantibodies and response to α‐interferon in patients with chronic viral hepatitis. J Hepatol 1990; 11: 339–43
   PubMedGoogle Scholar
• Fattovich G, Betterle C, Brollo L, Pedini L, Guistina G, Realdi G, et al. Autoantibodies during α‐interferon therapy for chronic hepatitis. Br J Med Virol 1991; 34: 132–5
   PubMed Web of Science ®Google Scholar
• Fried M W, Draguesku J O, Shindo M, Simpson L H, Steven M B, Hoofnagle J H, et al. Clinical and serological differentiation of autoimmune and hepatitis C virus‐related chronic hepatitis. Dig Dis Sci 1993; 4: 631–6
   Google Scholar
• Fridman W H, Gresser I, Bandu M T, Aguet M, Neauport‐Sautes C. Interferon enhances the expression of Fc γ receptors. J Immunol 1980; 5: 2436–41
   Google Scholar
• Itoh K, Inoue M, Kataoka S, Kumagami K. Differential effect of interferon expression of IgG‐ and IgM‐Fc receptors on human lymphocyte. J Immunol 1980; 6: 2589–95
   Google Scholar
• Rhodes J, Jones D H, Bleehen N M. Increased expression of human monocyte HLA‐DR antigens and Fc γ receptors in response to interferon in vivo. Clin Exp Immunol 1983; 53: 739–43
   PubMed Web of Science ®Google Scholar
• Schattner A. Interferons and autoimmunity. Am J Med Sci 1998; 295: 532–44
   Google Scholar
• Vento S, Perri G D, Garofano T, Cosco L, Conica E, Ferraro T, et al. Hazards of interferon therapy for HBV‐seronegative chronic hepatitis. Lancet 1989; 2: 926
   PubMed Web of Science ®Google Scholar
• Shindo M, Bisceglie A M D, Hoofnagle J H. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102: 1406–8
   PubMedGoogle Scholar
• Silva M O, Reddy K R, Jeffers L J, Hill M, Schiff E R. Interferon‐induced chronic active hepatitis?. Gastroenterology 1991; 101: 840–2
   PubMedGoogle Scholar
• Marcellin P, Pouteau M, Renard P, Grynblat J M, Linhart Colas N, Bordet P, et al. Sustained hypothyroidism induced by recombinant α interferon in patients with chronic hepatitis C. Gut 1992; 33: 855–6
   PubMedGoogle Scholar
• Hirohata S, Inoue T, Ito K. Development of rheumatoid arthritis after chronic hepatitis caused by hepatitis C virus infection. Int Med 1992; 31: 493–5
   PubMedGoogle Scholar
• Conlon K C, Uraba W J, Smith J W I. I, Steis R G, Longo D L, Clark J W. Exacerbation of symptoms of autoimmune disease in patients receiving alfa‐interferon therapy. Cancer 1990; 65: 2237–42
   PubMed Web of Science ®Google Scholar
• Clifford B D, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalences of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613–9
   PubMed Web of Science ®Google Scholar
• Osada K, Sameshima Y, Fujii H, Shimizu M, Watanabe J, Nishioka K. Effect of blood screening for anti‐HCV antibody by the second‐generation passive hemagglutination test on the incidence of post‐transfusion hepatitis. Viral hepatitis and liver disease, K Nishioka. Springer‐Verlag, Hong Kong 1994; 562–4
   Google Scholar
• Ulrich P P, Romeo J M, Lane P K, Kelly I, Daniel L J, Vyas G N. Detection, semiquantitation, and genetic variation in hepatitis C virus sequence amplified from the plasma of blood donors with elevated alanine aminotransferase. J Clin Invest 1990; 86: 1609–14
   PubMed Web of Science ®Google Scholar
• Johnson P J, McFarlane I G. Meeting report: international autoimmune hepatitis group. Hepatology 1993; 18: 998–1005
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877–83
   PubMed Web of Science ®Google Scholar
• Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type‐specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673–9
   PubMed Web of Science ®Google Scholar
• Knodell R G, Ishak K G, Black W C, Chen T S, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology 1981; 1: 431–5
   PubMed Web of Science ®Google Scholar
• Robertson D A, Zhang S L, Guy E C, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 1987; 2: 9–11
   PubMedGoogle Scholar
• Esteban J I, Esteban R, Viladomiu L, Talavera Lopez J C, Gonzalez A, Hernandez J M, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; 2: 294–7
   PubMed Web of Science ®Google Scholar
• McFarlane I G, Smith H M, Johnson P J, Bray G P, Vergani D, Williams R, et al. Hepatitis C virus antibodies in chronic active hepatitis: pathogenic factor or false positive result?. Lancet 1990; 335: 754–57
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Toda G, Hashimoto N, Kurokawa K. Antibody to superoxide dismutase, autoimmune hepatitis, and antibody for hepatitis C virus. Lancet 1990; 335: 1345–6
   PubMedGoogle Scholar
• Nishiguchi S, Kuroki T, Ueda T, Fukuda K, Takeda T, Nakajima S, et al. Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med 1992; 116: 21–5
   PubMed Web of Science ®Google Scholar